NCT05106205View on ClinicalTrials.gov

Phamacokinetics and Safety Profiles of DA-5213 10mg in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 21, 2021

Primary Completion Date

January 20, 2022

Study Completion Date

January 20, 2022

Conditions
Healthy
Interventions
DRUG

DA-5213 10mg

single dose administration (one tablet once a day)

DRUG

DA-5213-R 10mg

single dose administration (one tablet once a day)

Trial Locations (1)

15079

Central Hospital, Siheung-si

All Listed Sponsors
lead

Dong-A ST Co., Ltd.

INDUSTRY

NCT05106205 - Phamacokinetics and Safety Profiles of DA-5213 10mg in Healthy Subjects | Biotech Hunter | Biotech Hunter